García-García, 314 patient melatonin prophylaxis RCT: 108% more cases [p=0.26] https://c19p.org/garciagarcia
copied to clipboard
Melatonin in the Prophylaxis of SARS-CoV-2 Infection in Healthcare Workers (MeCOVID): A Randomised Clinical Trial
et al., Journal of Clinical Medicine, doi:10.3390/jcm11041139
PrEP RCT healthcare workers in Spain, showing no significant
difference in cases with melatonin prophylaxis. Most cases were asymptomatic
or paucisymtomatic, there were two symptomatic cases, no moderate/severe
cases, and no hospitalization.
The registered primary outcome is symptomatic cases. Authors
report on all cases due to the small number of symptomatic cases. They did not
include the original primary outcome results in the paper, but have provided
the results via email to a contributor.
The dosage in this trial is very low, 2mg daily. Meta
regression suggests higher doses are much more effective.
MeCOVID. EudraCT 2020-001530-35. NCT04353128 (history).
|
risk of symptomatic case, 7.4% lower, RR 0.93, p = 1.00, treatment 1 of 163 (0.6%), control 1 of 151 (0.7%), NNT 2051, primary outcome.
|
|
risk of case, 108.4% higher, RR 2.08, p = 0.26, treatment 9 of 163 (5.5%), control 4 of 151 (2.6%), post-hoc primary outcome.
|
| Effect extraction follows pre-specified rules prioritizing more serious outcomes. Submit updates |
García-García et al., 21 Feb 2022, Double Blind Randomized Controlled Trial, placebo-controlled, Spain, peer-reviewed, 25 authors.
Please send us corrections, updates, or comments. Vaccines and
treatments are complementary. All practical, effective, and safe means should
be used based on risk/benefit analysis. No treatment, vaccine, or intervention
is 100% available and effective for all current and future variants. We do not
provide medical advice. Before taking any medication, consult a qualified
physician who can provide personalized advice and details of risks and
benefits based on your medical history and situation. FLCCC and WCH
provide treatment protocols.